New hope to shield kidneys from harsh chemo damage
NCT ID NCT07018622
Summary
This study is testing whether a drug called dapagliflozin can protect the kidneys of cancer patients receiving platinum-based chemotherapy. Researchers will compare kidney injury markers in about 46 patients who either receive the drug or a placebo. The goal is to see if this approach can prevent a common and serious side effect of cancer treatment without interfering with its effectiveness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán"
RECRUITINGMéxico, Tlalpan, 14080, Mexico
Conditions
Explore the condition pages connected to this study.